Background: Glycogen synthase kinase 3 beta (GSK3beta) is a multifunctional serine/threonine kinase, which plays a major role in various signaling pathways. More than two decades after its discovery, various pharmaceutical companies are focusing on this protein as a target of interest for various therapeutic conditions.
Objective: To discuss the major developments in the area of GSK3beta as a therapeutic target globally and its role in disease physiology and give an overview of the classes of compounds designed for its inhibition.